RASSF1A hypermethylation and its inverse correlation with BRAF and/or KRAS mutations in MSI-associated endometrial carcinoma

International Journal of Cancer. Journal International Du Cancer
Sokbom KangSeung Myung Dong

Abstract

Both hypermethylation of the tumor suppressor gene RASSF1A and activating mutations of the KRAS and/or BRAF gene have been reported in a variety of human cancers. To investigate these epigenetic and genetic alterations in endometrial carcinoma (EC), we examined their frequency in 4 uterine EC cell lines and in 75 sporadic primary ECs. Using methylation specific PCR, we found RASSF1A methylation in 25 of 75 (33.3%) ECs. RASSF1A methylation was significantly associated with microsatellite instability (MSI, p < 0.001) and also with hMLH1 methylation (p < 0.001). KRAS mutations were detected in 14 of 75 (18.7%) ECs. BRAF mutations were identified in only 3 of 75 (4.0%) ECs and were not found in ECs with KRAS mutations or RASSF1A methylation. RASSF1A methylation was more frequent in KRAS mutation-negative ECs than in KRAS mutation-positive ECs (37.7% vs 14.3%), but this inverse correlation is not statistically significant (p = 0.122). However, we observed that RASSF1A methylation was inversely correlated with KRAS and/or BRAF mutations (p = 0.028) in MSI-negative ECs, while this inverse correlation disappeared in MSI-positive ECs. Furthermore, in MSI-positive ECs, 2 cases of concomitant RASSF1A methylation and KRAS mutation were fou...Continue Reading

References

Aug 17, 1994·Journal of the National Cancer Institute·B D DugganD Shibata
Sep 3, 1996·Proceedings of the National Academy of Sciences of the United States of America·J G HermanS B Baylin
Oct 24, 1998·Gynecologic Oncology·T SakamotoN Wake
Sep 22, 2000·The Journal of Biological Chemistry·M D VosG J Clark
Feb 17, 2001·The Journal of Pathology·H LagardaJ Prat
May 3, 2001·Journal of the National Cancer Institute·D G BurbeeJ D Minna
Jun 8, 2001·Proceedings of the National Academy of Sciences of the United States of America·K DreijerinkE R Zabarovsky
May 25, 2002·Molecular and Cellular Biology·Latha ShivakumarMichael A White
May 29, 2002·Oncogene·Manon van EngelandJames G Herman
Jun 18, 2002·Nature·Helen DaviesP Andrew Futreal
Aug 29, 2002·Nature·Harith RajagopalanVictor E Velculescu
Jun 12, 2003·Gynecologic Oncology·Allan CovensUNKNOWN Gynecologic Oncology Group
Nov 13, 2003·British Journal of Cancer·J W LeeS H Lee
May 1, 2004·American Journal of Obstetrics and Gynecology·David G MutchPaul J Goodfellow
Feb 22, 2005·International Journal of Cancer. Journal International Du Cancer·Helga B SalvesenLars A Akslen
Sep 8, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yu-Zhen FengIkuo Konishi

❮ Previous
Next ❯

Citations

May 13, 2008·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Judit PallarésXavier Matias-Guiu
Jan 1, 2010·Journal of Experimental & Clinical Cancer Research : CR·Tao WangGang Wu
Nov 13, 2015·Expert Opinion on Pharmacotherapy·Alfonso Duenas-GonzalezEli Fernández-de Gortari
Jun 15, 2010·Epigenetics : Official Journal of the DNA Methylation Society·Meng Hua Tao, Jo L Freudenheim
Dec 27, 2011·Cancer Biology & Therapy·Shannon N Westin, Russell R Broaddus
May 5, 2017·Epigenomics·Carla BartoschCarmen Jerónimo
Apr 12, 2008·International Journal of Cancer. Journal International Du Cancer·Xiaoyun LiaoAnnie Nga-Yin Cheung
Feb 2, 2013·Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B·Mai HeCynthia Jackson
Jun 18, 2016·Oncology Letters·Y U WuWeiguo Jin
Nov 29, 2017·Molecular and Clinical Oncology·Megumi YanokuraDaisuke Aoki
Dec 16, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J M A PijnenborgP G Groothuis
Mar 17, 2007·Pathology·Annie N Y Cheung

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.